Abstract Number: 2491 • ACR Convergence 2023
Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort
Background/Purpose: In 2022, ACR and EULAR proposed new classification criteria for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) based on a numerical item scoring…Abstract Number: 0688 • ACR Convergence 2023
Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
Background/Purpose: Avacopan, a selective C5aR1 inhibitor, has demonstrated efficacy and safety over 52 weeks in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. However, efficacy and…Abstract Number: 0709 • ACR Convergence 2023
Survival of Adults with IgA Vasculitis
Background/Purpose: Data on survival of adults with IgA vasculitis (IgAV) are scarce. The aim of our study was to estimate for the first time the…Abstract Number: 1248 • ACR Convergence 2023
Thrombotic Manifestations in Pediatric Behçet Disease Patients: A Multicentre Comparative Study from EUROFEVER Registry
Background/Purpose: Arterial and venous thrombosis occurs in 6.6 to 38.4% of pediatric Behçet disease (BD) and cerebral sinus is one of the most involved districts.…Abstract Number: 1565 • ACR Convergence 2023
Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
Background/Purpose: It has been reported that up to a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It is currently…Abstract Number: 1941 • ACR Convergence 2023
Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations
Background/Purpose: There is limited information on VEXAS syndrome in the Latin-American population. We aimed to identify UBA1 mutations causing VEXAS syndrome in Mexican patients presenting…Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…Abstract Number: 2492 • ACR Convergence 2023
The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life
Background/Purpose: Neurologic involvement (NI) is a common manifestation in patients with ANCA-associated vasculitis (AAV) and can lead to chronic pain and disability. This project assessed…Abstract Number: 0690 • ACR Convergence 2023
Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in…Abstract Number: 0710 • ACR Convergence 2023
The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review
Background/Purpose: IgA vasculitis (IgAV) is associated with malignancy in adult patients [1,2]. The clinical characteristics, temporal relationship, and underlying mechanisms of malignancy-associated IgAV are not…Abstract Number: 1250 • ACR Convergence 2023
Local Inflammatory Response Mediated by the Homing of Tfh17 Cells Is Involved in Tissue Injury of Immunoglobulin a Vasculitis
Background/Purpose: Immunoglobulin A vasculitis (IgAV), also named Henoch–Schönlein purpura, is a systemic vasculitis characterized by the deposition of IgA1-dominant immune complexes in small vessels that…Abstract Number: 1567 • ACR Convergence 2023
Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis
Background/Purpose: Damage is the irreversible consequence of disease or its treatment. This study aimed to evaluate the accrual of damage in Takayasu's arteritis (TAK) using…Abstract Number: 2051 • ACR Convergence 2023
Screening Multisystem Inflammatory Syndrome in Children: Accuracy of SickKids Screening Pathway Compared to ACR Algorithm
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C), also known as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS), is one of the most serious…Abstract Number: 2407 • ACR Convergence 2023
Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a medium and large vessel vasculitis with pathognomonic granulomatous infiltrates in the vessel wall. During the early stages of…Abstract Number: 2495 • ACR Convergence 2023
Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis
Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 35
- Next Page »